ArticleData in brief2025
Quantitative proteomic data of flotillin-2 interactome within detergent resistant membranes of HeLa cells.
Article in Data in brief, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Flotillin-binding protein networks serve as scaffolds, organizing lipid rafts and facilitating the recruitment of other raft-associated proteins such as receptors and downstream signaling molecules to regulate various intracellular pathways, including those involved in cell proliferation, migration, and endocytosis. Flotillins belong to the SPFH (stomatin/prohibitin/flotillin/HflK/C) domain-containing protein family, also known as the prohibitin homology (PHB) domain, which enables membrane association via acylation and hydrophobic hairpin motifs that anchor them to the inner leaflet of the plasma membrane. The functional diversity of flotillin proteins within membrane microdomains primarily stems from their interactions with other proteins. Data presented in this article characterize the proximal interactome of flotillin-2 within detergent-resistant membranes (DRMs) using BioID, a proximity-dependent biotinylation technique. Flotillin-2 was fused with the biotin ligase BirA* at either the N- or C-terminus and expressed in HeLa cells. DRMs were isolated through sucrose density gradient ultracentrifugation, and biotinylated proteins were purified using biotin-avidin affinity followed by label-free quantitative (LFQ) mass spectrometry. This approach identified a set of proteins significantly enriched in DRM fractions from cells expressing flotillin-2-BirA* fusions compared to control cells expressing BirA*-mEGFP. The two analyses allowed for relative quantification of ∼433 and ∼926 unique proteins across the N-terminal and C-terminal BirA* fusions, respectively. 28 (N-terminal) and 88 (C-terminal) proteins were observed as significantly enriched in flotillin-2 samples (28 and 43 with fold change ≥ 2). These enriched proteins are candidate interactors of flotillin-2 within membrane raft domains. Notably, the N-terminal fusion-associated proteins were significantly linked to specific biological processes such as dendritic transport and regulation of signal transduction, whereas the C-terminal fusion group showed enrichment in membrane biogenesis-related proteins. Among here presented DRM partners of flotillin-2, both previously known and earlier unreported interactors of this protein were found. Overall, our BioID-based analysis provides valuable insight into the flotillin-2 interactome in DRM fractions and lays the groundwork for future studies exploring the regulation of membrane lateral heterogeneity and the role of flotillin-mediated domains in signaling pathways, particularly those dysregulated in diseases such as cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.